4-(4-(((2R,3R)-3-(3-carbamimidoylbenzyl)-4-methoxy-4-oxobutan-2-yl)carbamoyl)phenyl)pyridine 1-oxide 4-(4-(((2R,3R)-3-(3-氨基甲酰亚胺基苄基)-4-甲氧基-4-氧代丁烷-2-基)氨基甲酰基)苯基)吡啶1-氧化物
CAS 193153-04-7 MFCD93153047
化学结构图
SMILES: COC(=O)C(Cc1cccc(C(=N)N)c1)C(C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1
化学属性
| Mol. Weight | 446.5 |
|---|---|
| Mol. Formula | C25H26N4O4 |
别名和识别编码
| CAS Number | 193153-04-7 |
|---|---|
| Chemical Name | 4-(4-(((2R,3R)-3-(3-carbamimidoylbenzyl)-4-methoxy-4-oxobutan-2-yl)carbamoyl)phenyl)pyridine 1-oxide |
| Synonym | ######## 2-(3-carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester 2-(R)-(3-carbamimidoylbenzyl)-3-(R)-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester FXV 673 FXV-673 FXV673 otamixaban |
| Chemical Name Translation | 4-(4-(((2R,3R)-3-(3-氨基甲酰亚胺基苄基)-4-甲氧基-4-氧代丁烷-2-基)氨基甲酰基)苯基)吡啶1-氧化物 |
| PubChem Substance ID | 5496659 |
| InChI | InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1 |
| LabNetwork Molecule ID | LN01304404 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Amines
- Aromatics
- Heterocycles
- Inhibitors
- Pharmaceuticals
- Intermediates & Fine Chemicals
产品应用
- ########
相关文献及参考
- [2]. Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2009 Sep 5;374(9692):787-95. Epub 2009 Aug 28
- [3]. Guertin KR, Choi YM.The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Curr Med Chem. 2007;14(23):2471-81.
- [4]. Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators.Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.Circulation. 2007
- [5]. Guertin, Kevin R.; Choi, Yong-Mi.The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development.Current Medicinal Chemistry (2007), 14(23), 2471-2481.
- Guertin, K.R. et al.: Curr. Med. Chem., 14, 2471 (2007); Hinder, M. et a
